Almost 200 jobs to be created
As a result of €15.5m in EU funding, nanoscience research institute CRANN, Cellix Ltd. and Radisens Technology will create 17 new R&D jobs and lead two major European nano research projects in the areas of cancer research and next-generation computer chips. Five leading multinational companies have also confirmed the availability of 175 job vacancies in the IT, telecommunications, customer service, HR consultancy and pharmaceutical industries at East Point Office Park.
The companies hiring, Oracle, Conduit, Citrix, Quintiles and Peninsula, are targeting graduates and experienced professionals for roles in sales, finance and business development, as well as technical support, customer service with languages and life science graduates for clinical and commercial operations.
East Point Office Park also announced it will host a Jobs Fair on Friday, April 16 for companies based at the established docklands office park beside Dublin city centre.
Prof Dermot Kelleher, head of TCD School of Medicine and IMM director, said that the EU funding of €10m was a “huge vote of confidence” for Ireland and that it recognised our leadership in the field of nanotechnology.
“This research programme will address some of the most important questions in human medicine relating to diagnosis and treatment of cancer, using 21st-century experience and know-how in nanotechnology, and we are looking forward to the time when our patients here will benefit from these innovative technologies,” he added.
Meanwhile, CRANN, the nanoscience research institute based at TCD and UCC and two Irish SMEs are also participating in the programme, Cellix Ltd. and Radisens Technology after being awarded €15.5m in non-Exchequer funding to lead two major European nano research projects.
In partnership with Intel, CRANN will also lead a European consortium focussed on the development of the next generation of electronic chip which will drive faster, lighter and more efficient computers, mobile phones and home gaming machines.
Prof. John Boland, director of CRANN said: “Investment in building Ireland’s R&D capability over the past ten years is delivering returns by attracting industry and academic based funding into Ireland and creating new jobs. Ireland is now globally recognized for its expertise in the area of nanoscience, as evidenced by the large amounts of non-exchequer funding we are winning through competitive international research projects. Research is a global competition and we need to continue to develop our knowledge base and expertise to make Ireland a true Innovation Centre.”
Professor Dermot Kelleher, head of TCD School of Medicine and IMM director said: “This is a huge vote of confidence and recognises Irish leadership in the cutting edge field of nanomedicine. This research programme will address some of the most important questions in human medicine relating to diagnosis and treatment of cancer, using 21st century experience and know-how in nanotechnology, and we are looking forward to the time when our patients here will benefit from these innovative technologies.”
|
|
